# Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms

> **NCT00082784** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 93 (actual)

## Conditions studied

- Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Nodal Marginal Zone Lymphoma
- Recurrent Adult Diffuse Large Cell Lymphoma
- Recurrent Adult Diffuse Mixed Cell Lymphoma
- Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
- Recurrent Grade 1 Follicular Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- Recurrent Grade 3 Follicular Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Marginal Zone Lymphoma
- Refractory Plasma Cell Myeloma
- Splenic Marginal Zone Lymphoma
- Waldenstrom Macroglobulinemia

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Alvocidib Hydrochloride
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT00082784
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2012-10
- **Final completion:** 2014-09
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2014-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00082784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00082784, "Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00082784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*